FDA Awarded Aeterna Zentaris (AEZS) Special Protocol Assessment for Phase 3 Registration Trial in Endometrial Cancer with AEZS-108


Aeterna Zentaris Granted Patent by EPO for AEZS-130 in Growth Hormone Deficiency Diagnosis (AEZS, CPST)


Aeterna Zentaris and Hikma Pharmaceuticals Sign a Commercialization and Licensing Agreement for Lead Oncology Compound, Perifosine, for Middle East and North Africa (MENA) Region


(AEZS, CALL, FWLT) PennyOmega.com Watch List for Friday Nov. 25, 2011


Aeterna Zentaris Announces Favorable Top-Line Results of Completed Phase 3 Study on AEZS-130 as First Oral Diagnostic Test for Adult Growth Hormone Deficiency


  • Video

  • Hot stocks to watch!

    JA Solar Holdings Co Ltd - JASO

    LM Ericsson Telephone Co - ERIC

    Bank of America Corporation - BAC

    Crown Equity Holdings Inc. - CRWE.OB

    ProShares UltraShort S&P500 ETF - SDS

    MGM Mirage Inc - MGM

    iShares Russell 2000 Index Fund - IWM

    QUALLCOMM Inc - QCOM

    Mattel, Inc - MAT

    Comcast Corp New - CMCSA

    Starbucks Corp - SBUX

    Citigroup Inc - C

    Ford Motor Co - F

    Staples Inc - SPLS

    Cleantech Transit, Inc. - CLNO.OB

    Freeport-McMoRan Copper & Gold - FCX

    Applied Materials Inc - AMAT

    General Electric Co - GE

    Baidu Inc - BIDU

    Seagate Technology Plc - STX

    Fifth Third Bancorp - FITB

    Mylan Laboratories Inc - MYL

  •